scholarly journals In Vitro and In Vivo Performance of Dry Powder Inhalation Formulations: Comparison of Particles Prepared by Thin Film Freezing and Micronization

2014 ◽  
Vol 15 (4) ◽  
pp. 981-993 ◽  
Author(s):  
Yi-Bo Wang ◽  
Alan B. Watts ◽  
Jay I. Peters ◽  
Sha Liu ◽  
Ayesha Batra ◽  
...  
Keyword(s):  
Thin Film ◽  
Dry Powder Inhalation ◽  
Dry Powder ◽  
Thin Film Freezing

scholarly journals Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

Pharmaceutics ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 1002
Author(s):  
Sawittree Sahakijpijarn ◽  
Chaeho Moon ◽  
John J. Koleng ◽  
Dale J. Christensen ◽  
Robert O. Williams
Keyword(s):  
Thin Film ◽  
Drug Loading ◽  
Dry Powder Inhaler ◽  
Drug Dissolution ◽  
Outpatient Basis ◽  
Dry Powder ◽  
Aerosol Performance ◽  
Thin Film Freezing

Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF). TFF produces brittle matrix nanostructured aggregates that are sheared into respirable low-density microparticles upon aerosolization from a passive dry powder inhaler. In vitro aerodynamic testing demonstrated that drug loading and excipient type affected the aerosol performance of remdesivir. Remdesivir combined with optimal excipients exhibited desirable aerosol performance (up to 93.0% FPF< 5 µm; 0.82 µm mass median aerodynamic diameter). Remdesivir was amorphous after the TFF process, which benefitted drug dissolution in simulated lung fluid. TFF remdesivir formulations are stable after one month of storage at 25 °C/60% relative humidity. An in vivo pharmacokinetic evaluation showed that TFF remdesivir–leucine was poorly absorbed into systemic circulation while TFF remdesivir-Captisol® demonstrated increased systemic uptake compared to leucine. Remdesivir was hydrolyzed to the nucleoside analog GS-441524 in the lung, and levels of GS-441524 were greater in the lung with leucine formulation compared to Captisol®. In conclusion, TFF technology produces high-potency remdesivir dry powder formulations for inhalation that are suitable to treat patients with COVID-19 on an outpatient basis and earlier in the disease course where effective antiviral therapy can reduce related morbidity and mortality.

scholarly journals Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

2020 ◽  
Author(s):  
Sawittree Sahakijpijarn ◽  
Chaeho Moon ◽  
John J. Koleng ◽  
Dale J. Christensen ◽  
Robert O. Williams
Keyword(s):  
Thin Film ◽  
Drug Loading ◽  
Dry Powder Inhaler ◽  
Drug Dissolution ◽  
Outpatient Basis ◽  
Dry Powder ◽  
Aerosol Performance ◽  
Thin Film Freezing

AbstractRemdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for Emergency Use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF). TFF produces brittle matrix nanostructured aggregates that are sheared into respirable low-density microparticles upon aerosolization from a passive dry powder inhaler. In vitro aerodynamic testing demonstrated that drug loading and excipient type affected the aerosol performance of remdesivir. Remdesivir combined with optimal excipients exhibited desirable aerosol performance (up to 93.0% FPF; 0.82μm MMAD). Remdesivir was amorphous after the TFF process, which benefitted drug dissolution in simulated lung fluid. TFF remdesivir formulations are stable after one-month storage at 25 °C/60%RH. In vivo pharmacokinetic evaluation showed that TFF-remdesivir-leucine was poorly absorbed into systemic circulation while TFF-remdesivir-Captisol® demonstrated increased systemic uptake compared to leucine. Remdesivir was hydrolyzed to the nucleoside analog GS-441524 in lung, and levels of GS-441524 were greater in lung with the leucine formulation compared to Captisol®. In conclusion, TFF technology produces high potency remdesivir dry powder formulations for inhalation suitable to treat patients with COVID-19 on an outpatient basis and earlier in the disease course where effective antiviral therapy can reduce related morbidity and mortality.

A new agglomerated KSR-592 β-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo

2003 ◽  
Vol 88 (1) ◽  
pp. 23-33 ◽  
Author(s):  
Kazuhiko Ikegami ◽  
Yoshiaki Kawashima ◽  
Hirofumi Takeuchi ◽  
Hiromitsu Yamamoto ◽  
Kazuki Mimura ◽  
...  
Keyword(s):  
Dry Powder Inhalation ◽  
Dry Powder ◽  
Crystal System

In vivo and in vitro application of thin film interferometry to assess contact lens wettability

2018 ◽  
Vol 41 ◽  
pp. S9
Author(s):  
Raied Fagehi ◽  
Ian Pearce ◽  
Katherine Oliver ◽  
Alan Tomlinson
Keyword(s):  
Thin Film ◽  
Contact Lens

scholarly journals Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 535 ◽  
Author(s):  
Edit Benke ◽  
Árpád Farkas ◽  
Piroska Szabó-Révész ◽  
Rita Ambrus
Keyword(s):  
In Silico ◽  
Chronic Obstructive ◽  
Dry Powder Inhalation ◽  
Dry Powder ◽  
Aerodynamic Properties ◽  
Drug Concentrations ◽  
Anti Inflammatory ◽  
New Formulation ◽  
Spray Dried

Most of the marketed dry powder inhalation (DPI) products are traditional, carrier-based formulations with low drug concentrations deposited in the lung. However, due to their advantageous properties, their development has become justified. In our present work, we developed an innovative, carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with suitable shape and size for pulmonary application. Meloxicam potassium, a nonsteroidal anti-inflammatory drug (NSAID), was used as an active ingredient due to its local anti-inflammatory effect and ability to decrease the progression of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The results of the in vitro and in silico investigations showed high lung deposition in the case of this new formulation, confirming that the interparticle interactions were changed favorably.

scholarly journals In vitro and Short-term in vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor

2003 ◽  
Vol 19 (11) ◽  
pp. 1481-1486 ◽  
Author(s):  
Sun Kil KANG ◽  
Ran-A JEONG ◽  
Sejin PARK ◽  
Taek Dong CHUNG ◽  
Sunmin PARK ◽  
...  
Keyword(s):  
Thin Film ◽  
Glucose Sensor ◽  
Short Term
Sign in / Sign up

Export Citation Format

Share Document